Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02092649
Recruitment Status : Completed
First Posted : March 20, 2014
Results First Posted : January 6, 2016
Last Update Posted : January 6, 2016
Sponsor:
Information provided by (Responsible Party):
Lawrence Spriet, University of Guelph

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Fatty acids are the main components of the cell membranes. It has been demonstrated that diet can alter the characteristics and function of many membranes in the body, which has an effect on cardiovascular and metabolic health. Over the last two decades there has been a substantial rise in the research of the effects of Omega 3 polyunsaturated fatty acids on bodily function. There are two fatty acids that are of particular interest to researchers, eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). These fatty acids have unique unsaturated structures, and their incorporation into biological membranes seems to generate important and positive physiological effects. The body is unable to synthesize these fatty acids in high concentrations to elicit significant effects, so they must be obtained through diet in food or via supplementation.

It has been suggested that EPA and DHA supplementation increases resting metabolic rate (RMR) in humans, in part by increasing the use of fat as a fuel during rest. There are a limited number of studies examining the effects of Omega 3 supplementation on RMR. Some have found an increase in RMR while others have found no change. These studies have some limitations, as that they have either used a small sample size, a low omega fatty acid dose and/or short supplementation periods. Due to the variable results, the investigators will improve the reliability of the RMR measurements by making measures on each subject during two consecutive days at each time point that it is measured (0, 6 and 12 weeks).

Therefore, the purpose of this study is to determine the effects of 12 weeks of omega 3 supplementation (3 g/d) on healthy young adults vs. the supplementation of a placebo. The researchers hypothesize that EPA and DHA supplementation will result in an increase in RMR and fat oxidation in some subjects and not in others. The duplicate RMR measures will determine the prevalence and magnitude of the omega 3 supplementation.


Condition or disease Intervention/treatment Phase
Whole Body Energy Metabolism Dietary Supplement: Omega-3 Complete Dietary Supplement: Placebo Pill Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate
Study Start Date : April 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Omega-3 Complete
Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
 Dietary Supplement: Omega-3 Complete
Placebo Comparator: Placebo Pill
Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
 Dietary Supplement: Placebo Pill


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in Resting Metabolic Rate From Baseline [ Time Frame: Baseline, 6 weeks, 12 weeks ]
    Percent change in resting metabolic rate


Secondary Outcome Measures :
  1. Change in Maximum Oxygen Consumption From Baseline [ Time Frame: Baseline, 12 weeks ]
  2. Change in Whole Body Resting Fat Oxidation From Baseline [ Time Frame: Baseline, 6 weeks, 12 weeks ]
  3. Change in Whole Body Resting Carbohydrate Oxidation From Baseline [ Time Frame: Baseline, 6 weeks, 12 weeks ]
  4. Variability of Resting Metabolic Rate Measurement on 2 Consecutive Days [ Time Frame: Baseline, 6 weeks, 12 weeks ]
  5. Change in Fasted Blood Triglyceride Concentration From Baseline [ Time Frame: Baseline, 12 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 - 30 years of age.
  • Must currently practice a consistent diet and exercise regimen, and maintain this throughout the duration of the study.

Exclusion Criteria:

  • Current or previous supplementation with omega-3's.
  • Average fish intake greater than two times per week.
  • Taken any medications, have any medical condition, and hospitalization or surgeries.
  • Allergy to fish/fish oil, , (rosemary extract, ascorbyl palmitate, or natural tocopherols).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02092649


Locations
Layout table for location information
Canada, Ontario
University of Guelph
Guelph, Ontario, Canada, N1G 2W1
Sponsors and Collaborators
University of Guelph
Investigators
Layout table for investigator information
Principal Investigator: Lawrence L Spriet, PhD University of Guelph
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Lawrence Spriet, Professor and Chair, University of Guelph
ClinicalTrials.gov Identifier: NCT02092649    
Other Study ID Numbers: 14JA044
First Posted: March 20, 2014    Key Record Dates
Results First Posted: January 6, 2016
Last Update Posted: January 6, 2016
Last Verified: December 2015
Keywords provided by Lawrence Spriet, University of Guelph:
Omega-3
Resting metabolic rate
Eicosapentaenoic acid
Docosahexaenoic acid